

RECEIVED
CENTRAL FAX CENTER



FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

55 Cambridge Parkway ■ Cambridge, MA 02142-1292 ■ 617.452.1600 ■ Fax 617.452.1666
www.finnegan.com

FACSIMILE TRANSMITTAL

TO

Name: Group Art Unit 1623; Examiner E. Peselev Date: April 26, 2005
Company: USPTO Phone Number:
Fax Number: (703) 872-9306 Total Pages (including cover): 46
Subject: Application No. 10/776,188 Confirmation Copy to Follow: N
Atty. Doc. 08505.0020-00000

FROM

Name: Maria T. Bautista Verified by: M. Bautista
Phone Number: 617-452-1621 Our File No.: 08505.0020-00000

MESSAGE

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R § 1.8

I hereby certify that the attached response (34 pages), and copies of Andreoli (3 pages) and Loudon (8 pages), are being transmitted by facsimile to the U.S. Patent and Trademark Office on April 26, 2005.

Maria Bautista

Maria T. Bautista
Reg. No. 52,516

MTB

If there is a problem with this transmission, please notify office services at 617-452-1617.

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify the sender immediately by telephone (collect), and return the original message by first-class mail to the above address.

RECEIVED
CENTRAL FAX CENTER

APR 26 2005

PATENT

Customer No. 22,852
Attorney Docket No. 08505.0020

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Jenkins, Peter James et al.) Group Art Unit: 1623
Application No.: 10/776,188) Examiner: E. Peselev
Filed: February 12, 2004)
For: PREPARATION AND DIABETIC) Confirmation No.: 3089
USE OF GIBBERELLINS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REPLY TO OFFICE ACTION

In reply to the Office Action mailed January 26, 2005, please amend the
above-identified application as follows:

Amendments to the Specification are included in this paper beginning at p. 2.

Amendments to the Claims are reflected in the listing of claims in this paper
beginning at p. 3.

Remarks/Arguments follow the amendment sections of this paper beginning at
p. 23.